8-K
filed January 31, 2025, 6:59 PM ET
ticker CLRB
CIK 0001279704
regulatory
confidence high
sentiment negative
materiality 0.75
Cellectar receives Nasdaq minimum bid price deficiency notice; 180-day cure period until July 29, 2025
Cellectar Biosciences, Inc.
- Notice from Nasdaq on Jan 30, 2025 for failure to maintain $1.00 minimum bid price per Nasdaq Listing Rule 5550(a)(2).
- No immediate impact on listing; common stock remains on Nasdaq Capital Market.
- Company has 180 calendar days, until July 29, 2025, to regain compliance.
- If not cured, Company may be eligible for an additional 180-day extension subject to meeting other listing standards.
- Failure to regain compliance could lead to delisting; Company may request a hearing to stay any delisting action.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-25-008127
- form_type
- 8-K
- ticker
- CLRB
- cik
- 0001279704
- company_name
- Cellectar Biosciences, Inc.
- filed_at
- 2025-01-31T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:03.175687+00:00
- generated_at
- 2026-05-27T04:36:10.785621+00:00
- sec_items
- ["3.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-25-008127
- json_url
- https://secwatch.observer/filing/0001104659-25-008127.json
- markdown_url
- https://secwatch.observer/filing/0001104659-25-008127.md
- text_url
- https://secwatch.observer/filing/0001104659-25-008127.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1279704/000110465925008127/0001104659-25-008127-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1279704/000110465925008127/tm255128d1_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
ILLR
Triller gets Nasdaq bid-price exception until June 30, 2026
Triller Group Inc.
June 2, 2026, 8:26 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 29, 2026, the Nasdaq Hearings Panel (the
“Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant
Triller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30,
2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following
a successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which
modified a previous December 26, 2025 decision by a Nasdaq Hearings Panel
Filing page
SEC filing
ISPC
iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum
iSpecimen Inc.
June 1, 2026, 5:00 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 29, 2026, iSpecimen Inc. (the “Company”)
received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum
of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report
on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May
29, 2026, the Company doe
Filing page
SEC filing
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY
Filing page
SEC filing
NUTR
NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026
NUSATRIP Inc
June 1, 2026, 7:10 AM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”)
from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s
non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely
file its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended
March 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req
Filing page
SEC filing
HWH
HWH International receives Nasdaq deficiency notice for equity below $2.5M threshold
HWH International Inc.
May 29, 2026, 5:21 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 29, 2026 HWH International Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’
equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) because the Company’s stockholders’
equity of $2,078,220 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 was below the
required minimum of $2.5 million, and because, as of May 29, 2026, the Company did
Filing page
SEC filing
ATNM
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
May 29, 2026, 5:10 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Filing page
SEC filing
CSAI
Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing
CLOUDASTRUCTURE, INC.
May 29, 2026, 5:09 PM ET
regulatory
Items 3.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 26, 2026, Cloudastructure,
Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq
Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for
the period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which
requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional
time to review and confirm the accounting treatment for its outstand
Filing page
SEC filing
EDBL
Edible Garden receives Nasdaq delisting notice for bid price non-compliance; intends to appeal
Edible Garden AG Inc
May 29, 2026, 5:00 PM ET
regulatory
Items 3.01
same fact type: exchange_compliance_notice
same SEC item: 3.01
same event type: regulatory
similar materiality
This filing
January 30, 2025, Cellectar Biosciences, Inc. (the “Company”)
received notice from Nasdaq which indicated that under Nasdaq Listing Rule 5550(a)(2), the Company is required to maintain a minimum bid
price for its common
Comparable filing
May 27, 2026, Edible Garden AG Incorporated (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for at least 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share (the “Bid Price Rule”). Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), because the Company has effected a reverse stock split over the prior one-year per
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.